RAPP · Rapport Therapeutics, Inc.
$47.42
+0.06 (+0.13%)
At close · Aug 14
Market Cap
$2.28B
Shares
47.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$111.48M
-42.4%
FY2025
Diluted EPS
-$2.86
+24.3%
FY2025
Operating Cash Flow
-$87.47M
-34.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $136.67M | $94.79M | $60.94M | $28M | |
| — | $30.31M | $22.12M | $8.18M | |
| — | $1.02M | $839K | $112K | |
| $173.52M | $125.1M | $83.06M | $36.18M | |
| -$153.52M | -$125.1M | -$83.06M | -$36.18M | |
| $16.36M | $13.62M | $12.14M | $2.53M | |
| $16.36M | $13.62M | $4.75M | $1.4M | |
| — | — | -$78.31M | -$34.78M | |
| — | $0 | $0 | $10K | |
| -$137.16M | -$111.48M | -$78.31M | -$34.79M | |
| -$138.35M | -$110.42M | -$78.83M | -$34.78M | |
| USD/shares | — | -$2.86 | -$3.78 | -$23.10 |
| USD/shares | — | -$2.86 | -$3.78 | -$23.10 |
| shares | — | 38.93M | 20.74M | 1.51M |
| shares | — | 38.93M | 20.74M | 1.51M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.30×
EV/EBIT
—
Peer median 22.07×
P/E (TTM)
—
Peer median 16.98×
Peer medians compare against the 258 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
2012593
CUSIP
75383L102
13F (30d)
156 filings
153 filers
Visit website
Investor relations